Edition:
United Kingdom

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

55.80USD
22 Nov 2017
Change (% chg)

$-0.32 (-0.57%)
Prev Close
$56.12
Open
$56.03
Day's High
$56.15
Day's Low
$55.58
Volume
814,009
Avg. Vol
1,541,791
52-wk High
$56.68
52-wk Low
$37.38

Select another date:

Mon, Nov 6 2017

BRIEF-Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan

* Abbott's mitraclip approved as first transcatheter mitral valve repair device in Japan Source text for Eikon: Further company coverage:

Fitch Withdraws Abbott Laboratories' Ratings

(The following statement was released by the rating agency) CHICAGO, November 02 (Fitch) Fitch Ratings has chosen to withdraw the ratings of Abbott Laboratories and St. Jude Medical, Inc. for commercial reasons. RATING SENSITIVITIES Ratings sensitivities are no longer relevant given today's withdrawal. FULL LIST OF RATING ACTIONS Fitch has affirmed and subsequently withdrawn the following ratings. Abbott Laboratories --Long-Term Issuer Default Rating 'BBB', Outlook Stable; --Senior unsecured ban

BRIEF-Abbott gets FDA clearance for its Alinity ci-series instruments

* Abbott announces FDA clearance for its Alinity ci-series next-generation diagnostic systems

BRIEF-Abbott says ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​

* Abbott - ‍secured FDA clearance for confirm Rx Insertable Cardiac Monitor​ Source text for Eikon: Further company coverage:

BRIEF-Abbott CFO says Alere is expected to contribute around $475 mln to reported sales this year

* Abbott CFO says Alere, is expected to contribute around $475 million to reported sales, and forecast a neutral impact on adjusted earnings per share this year - Conf Call

Abbott's recent deals, medical device pipeline to fuel growth

Abbott Laboratories' quarterly results beat estimates and the company raised the top end of its full-year earnings forecast range on Wednesday, as a string of recent deals and medical device approvals help spur growth in its largest unit.

UPDATE 3-Abbott's recent deals, medical device pipeline to fuel growth

* Shares up 2.8 pct to record high (Adds conference call details, updates shares)

BRIEF-Abbott Q3 adjusted EPS $0.66 from continuing operations

* Sees FY 2017 gaap earnings per share $0.97 to $0.99 from continuing operations

Abbott Labs posts quarterly profit vs. year-ago loss

Oct 18 Diversified healthcare company Abbott Laboratories on Wednesday reported a quarterly profit compared with a loss in the year-ago quarter, helped by strong sales in its medical devices and generics businesses.

BRIEF-Abbott completes cash tender offer for Series B Convertible Perpetual Preferred Stock of Alere Inc

* Abbott completes cash tender offer for Series B Convertible Perpetual Preferred Stock of Alere Inc. Source text for Eikon: Further company coverage:

Select another date: